LOS ANGELES, CA / ACCESSWIRE / January 15, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / January 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Cardlytics (CDLX) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Cardlytics, Inc. (CDLX) Q3 2024 Earnings Call Transcript
Cardlytics (CDLX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to earnings of $0.01 per share a year ago.
NEW YORK, NY / ACCESSWIRE / September 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ: CDLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ:CDLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / September 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ:CDLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / September 21, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ:CDLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / September 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ:CDLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / September 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ:CDLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / September 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cardlytics, Inc. ("Cardlytics") (NASDAQ:CDLX) concerning possible violations of federal securities laws. Cardlytics announced its second quarter 2024 financial results on August 7, 2024, revealing a 9% year-over-year decrease in revenue to $69.6 million, alongside a 3% decline in adjusted contribution to $36.4 million; the Company also disclosed that Karim Temsamani stepped down as Chief Executive Officer and from the Board of Directors.